CTOs on the Move

Locus Biosciences

www.locus-bio.com

 
Locus Biosciences` novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.locus-bio.com
  • 7020 Kit Creek Road Suite 210
    Research Triangle Park, NC USA
  • Phone: 919.313.9648

Executives

Name Title Contact Details

Funding

Locus Biosciences raised $19M on 11/14/2017

Similar Companies

Novacam Technologies

Novacam Technologies, Inc. is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cathay Industrial Biotech

Cathay Industrial Biotech is a Mt Zion, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Future Family

Future Family is where women, men and couples start their fertility journey. The company`s mission is to make fertility care accessible and affordable to all.

Arsanis Inc

Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.